-
Scientists develop affordable spit test for prostate cancer detection
01 Jun 2024 14:38 GMT
… promises to revolutionize prostate cancer detection by identifying … reducing unnecessary treatments.
Prostate cancer diagnoses are expected … turning the tide on prostate cancer by enabling earlier … life expectancy, the incidence of prostate cancer is rising. …
-
Multimodal, PSMA-Targeted, PAMAM Dendrimer-Drug Conjugates for Treatment of Prostate Cancer: Preclinical Evaluation
30 May 2024 09:26 GMT
… et al. Cancer incidence and mortality worldwide: sources … management of localized prostate cancer (Cancer Care Ontario … metastatic hormone sensitive prostate cancer: chemohormonal therapy and … radiation for oligometastatic prostate cancer: the ORIOLE Phase …
-
Prostate Cancer Treatment Market Size, Top Companies, Share, Growth And Forecast 2033
29 May 2024 18:01 GMT
… ;2653
Prostate Cancer Treatment Market Growth Drivers:
Increasing Incidence of Prostate Cancer: The growing incidence of prostate cancer …
-
CEACAM5-Targeted Immuno-PET in Androgen Receptor-Negative Prostate Cancer.
28 May 2024 19:04 GMT
… incidence of androgen receptor (AR)-negative (AR-) prostate cancer, including aggressive neuroendocrine prostate cancer … as it lacks typical prostate cancer hallmarks. The carcinoembryonic … diagnostic tool for AR- prostate cancer.
Journal of nuclear medicine …
-
Cabazitaxel/Abiraterone Yields PFS Improvement in mCRPC
02 Jun 2024 04:28 GMT
… patients with metastatic castration-resistant prostate cancer (mCRPC) and who have previously … ) plus docetaxel for hormone-sensitive prostate cancer (HSPC), according to results from … , and safety.
Regarding safety, the incidence of grade ≥3 adverse events …
-
ASCO 2024: PSMAfore: HRQoL and Pain in a Phase 3 Study of 177Lu-PSMA-617 in Taxane-Naïve Patients with mCRPC
02 Jun 2024 04:16 GMT
… taxane-naïve metastatic castration-resistant prostate cancer (mCRPC) patients treated with … receptor pathway inhibitor change:
The incidence of grade ≥3 adverse … patients with metastatic castration-resistant prostate cancer (VISION): A multicentre, open- …
-
Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting
01 Jun 2024 12:28 GMT
… previous reports, with a low incidence of neurologic treatment-emergent adverse … were grade 1 or 2. Incidence of neurologic TEAEs were low … of the world’s leading prostate cancer medicines. Nuvation Bio has offices …
-
Multiomics Opens the Door: More Data, More Insight into Biology’s Complexity
01 Jun 2024 10:41 GMT
… (AA) men in relation to prostate cancer (PCa). Tumor samples from this … AA men have a higher incidence and mortality rate than any … methylation changes in African American prostate cancer, Epigenetics, 18:1, 2180585, doi …
-
Australian bowel cancer screening change welcomed by Scot
01 Jun 2024 08:02 GMT
… in their 40s most affected.
Incidence rates for cancer in young … , Western Europe, and Australasia.
Globally, prostate cancer and cancer of the windpipe … year-on-year rise in incidence rates, but there were also …
-
Johnson & Johnson Submits Application To The European Medicines Agency Seeking Approval Of Subcutaneous Formulation Of RYBREVANT®▼ (Amivantamab) For The Treatment Of Patients With EGFR-Mutated Non-Small Cell Lung Cancer
31 May 2024 23:49 GMT
… 21 percent).1 Furthermore, VTE incidence was numerically lower in the … exploring how to decrease the incidence and/or severity of … deaths than breast cancer and prostate cancer combined. 21 The main … , et al. EGFR mutation incidence in non-small-cell lung …